Preclinical Study of a Combination of Erlotinib and Bevacizumab in Early Stages of Unselected Non-Small Cell Lung Cancer Patient-Derived Xenografts

Targeted Oncology
J RolffI Fichtner

Abstract

The differential outcomes of clinical studies of the targeted therapies for non-small cell lung cancer (NSCLC) indicate that better stratification of patients is required. This could be achieved with the help of patient-derived xenografts (PDX) of epidermal growth factor receptor (EGFR) wild-type patients resistant to erlotinib treatment. To explore the potential of patient-derived NSCLC xenografts to optimize therapy using 24 well-characterized early-stage NSCLC PDX. Patient tumor tissue was transplanted subcutaneously into nude mice. After engraftment, tumors were expanded and the sensitivity was tested. Gene expression analysis was used to identify differentially expressed genes between erlotinib responder (n = 3) and non-responder (n = 21). Tumor tissue was analyzed with TaqMan PCR, immunohistochemistry and ELISA to examine the response of the models. Gene expression analysis revealed vascular endothelial growth factor A (VEGFA) to be up-regulated in erlotinib non-responder. Because of that, the combination of erlotinib with bevacizumab was evaluated in one erlotinib-sensitive and four erlotinib-resistant PDX. Combination treatment was superior to monotherapy, leading to the highest and significant inhibition of tumor growt...Continue Reading

References

May 15, 2002·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Y D JungL M Ellis
Jun 12, 2003·British Journal of Cancer·H WildiersA T van Oosterom
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Oct 12, 2004·Hematology/oncology Clinics of North America·Lee M Ellis
Jul 15, 2005·The New England Journal of Medicine·Frances A ShepherdUNKNOWN National Cancer Institute of Canada Clinical Trials Group
Mar 4, 2006·Clinical Lung Cancer·Daniel Edmund Bryan Swinson, Kenneth John O'Byrne
Apr 13, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·James R TonraDaniel J Hicklin
Dec 15, 2006·The New England Journal of Medicine·Alan SandlerDavid H Johnson
Jul 3, 2008·Nature Clinical Practice. Oncology·Giampaolo TortoraGiampietro Gasparini
Jul 4, 2008·Nature Reviews. Cancer·Lee M Ellis, Daniel J Hicklin
Oct 18, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Iduna FichtnerJohannes Merk
Dec 24, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jian-ji PanYou-yong Lu
May 19, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·George N NaumovJohn V Heymach
Feb 2, 2010·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·J FerlayE Steliarova-Foucher
May 27, 2010·British Journal of Cancer·P WorkmanUNKNOWN Committee of the National Cancer Research Institute
Jun 24, 2010·Molecular Cancer Therapeutics·Sumanta Kumar PalKaren Reckamp
Feb 8, 2011·CA: a Cancer Journal for Clinicians·Ahmedin JemalDavid Forman
Mar 29, 2011·Pharmacology & Therapeutics·Annette K LarsenAmélie Petitprez
Nov 17, 2011·PloS One·Phillip YenAleksander S Popel
Feb 13, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott A Laurie, Glenwood D Goss
Jan 1, 2013·Microarrays·Ruprecht Kuner

❮ Previous
Next ❯

Citations

Aug 24, 2017·Expert Opinion on Therapeutic Targets·Daniela FrezzettiAntonella De Luca
Jul 22, 2018·International Journal of Clinical Oncology·Taichi TakashinaUNKNOWN Hokkaido Lung Cancer Clinical Study Group

❮ Previous
Next ❯

Related Concepts

Related Feeds

Arterial-Venous in Development & Disease

Arterial-venous development may play a crucial role in cardiovascular diseases. Here is the latest research.